Health Care [ 6/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.
The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 25 | -0.31 Increased by +72.42% | -0.10 Decreased by -206.10% |
| Nov 12, 24 | -0.19 Increased by +80.99% | -0.24 Increased by +20.79% |
| Aug 7, 24 | 0.45 Increased by +154.22% | -0.65 Increased by +169.23% |
| May 8, 24 | -1.01 Increased by +6.48% | -0.81 Decreased by -24.69% |
| Mar 5, 24 | -1.11 Decreased by -85.00% | -0.99 Decreased by -12.12% |
| Nov 14, 23 | -1.00 Increased by +43.18% | -1.03 Increased by +2.91% |
| Aug 14, 23 | -0.83 Increased by +58.91% | -1.15 Increased by +27.83% |
| May 3, 23 | -1.08 Increased by +66.25% | -1.22 Increased by +11.48% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.93 M Decreased by -72.61% | -19.52 M Increased by +65.65% | Decreased by -667.12% Decreased by -25.44% |
| Sep 30, 24 | 13.53 M Increased by +12.46% | -9.93 M Increased by +86.13% | Decreased by -73.39% Increased by +87.67% |
| Jun 30, 24 | 8.97 M Decreased by -75.12% | 24.88 M Increased by +159.11% | Increased by +277.45% Increased by +337.63% |
| Mar 31, 24 | 12.44 M Decreased by -70.12% | -52.67 M Decreased by -24.01% | Decreased by -423.59% Decreased by -315.07% |
| Dec 31, 23 | 10.68 M Decreased by -80.98% | -56.82 M Decreased by -145.53% | Decreased by -531.84% Decreased by -1.19 K% |
| Sep 30, 23 | 12.03 M Decreased by -10.25% | -71.64 M Decreased by -6.22% | Decreased by -595.30% Decreased by -18.35% |
| Jun 30, 23 | 36.05 M Increased by +167.38% | -42.09 M Increased by +45.64% | Decreased by -116.76% Increased by +79.67% |
| Mar 31, 23 | 41.62 M Increased by +393.78% | -42.48 M Increased by +47.52% | Decreased by -102.05% Increased by +89.37% |